Nicholas Feasey, Raheelah Ahmad, Elizabeth Ashley, Rifat Atun, Kate S Baker, Francesca Chiari, H Rogier van Doorn, Alison Holmes, Timothy Jinks, Andrew Jermy, Jyoti Joshi, Souha S Kanj, Matt King, Direk Limmathurotsakul, Janet Midega, Mirfin Mpundu, Jamie Nunn, Iruka N Okeke, Stuart Reid, Dawn Sievert, Paul Turner, Kamini Walia, Sharon J Peacock
{"title":"Insights of SEDRIC, the Surveillance and Epidemiology of Drug-Resistant Infections Consortium.","authors":"Nicholas Feasey, Raheelah Ahmad, Elizabeth Ashley, Rifat Atun, Kate S Baker, Francesca Chiari, H Rogier van Doorn, Alison Holmes, Timothy Jinks, Andrew Jermy, Jyoti Joshi, Souha S Kanj, Matt King, Direk Limmathurotsakul, Janet Midega, Mirfin Mpundu, Jamie Nunn, Iruka N Okeke, Stuart Reid, Dawn Sievert, Paul Turner, Kamini Walia, Sharon J Peacock","doi":"10.12688/wellcomeopenres.23494.1","DOIUrl":null,"url":null,"abstract":"<p><p>The increasing threat from infection with drug-resistant pathogens is among the most serious public health challenges of our time. Formed by Wellcome in 2018, the Surveillance and Epidemiology of Drug-Resistant Infections Consortium (SEDRIC) is an international think tank whose aim is to inform policy and change the way countries track, share, and analyse data relating to drug-resistant infections, by defining knowledge gaps and identifying barriers to the delivery of global surveillance. SEDRIC delivers its aims through discussions and analyses by world-leading scientists that result in recommendations and advocacy to Wellcome and others. As a result, SEDRIC has made key contributions in furthering global and national actions. Here, we look back at the work of the consortium between 2018-2024, highlighting notable successes. We provide specific examples where technical analyses and recommendations have helped to inform policy and funding priorities that will have real-world impact on the surveillance and epidemiology of infections with drug-resistant pathogens.</p>","PeriodicalId":23677,"journal":{"name":"Wellcome Open Research","volume":"10 ","pages":"5"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885901/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wellcome Open Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/wellcomeopenres.23494.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
Insights of SEDRIC, the Surveillance and Epidemiology of Drug-Resistant Infections Consortium.
The increasing threat from infection with drug-resistant pathogens is among the most serious public health challenges of our time. Formed by Wellcome in 2018, the Surveillance and Epidemiology of Drug-Resistant Infections Consortium (SEDRIC) is an international think tank whose aim is to inform policy and change the way countries track, share, and analyse data relating to drug-resistant infections, by defining knowledge gaps and identifying barriers to the delivery of global surveillance. SEDRIC delivers its aims through discussions and analyses by world-leading scientists that result in recommendations and advocacy to Wellcome and others. As a result, SEDRIC has made key contributions in furthering global and national actions. Here, we look back at the work of the consortium between 2018-2024, highlighting notable successes. We provide specific examples where technical analyses and recommendations have helped to inform policy and funding priorities that will have real-world impact on the surveillance and epidemiology of infections with drug-resistant pathogens.
Wellcome Open ResearchBiochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
CiteScore
5.50
自引率
0.00%
发文量
426
审稿时长
1 weeks
期刊介绍：
Wellcome Open Research publishes scholarly articles reporting any basic scientific, translational and clinical research that has been funded (or co-funded) by Wellcome. Each publication must have at least one author who has been, or still is, a recipient of a Wellcome grant. Articles must be original (not duplications). All research, including clinical trials, systematic reviews, software tools, method articles, and many others, is welcome and will be published irrespective of the perceived level of interest or novelty; confirmatory and negative results, as well as null studies are all suitable. See the full list of article types here. All articles are published using a fully transparent, author-driven model: the authors are solely responsible for the content of their article. Invited peer review takes place openly after publication, and the authors play a crucial role in ensuring that the article is peer-reviewed by independent experts in a timely manner. Articles that pass peer review will be indexed in PubMed and elsewhere. Wellcome Open Research is an Open Research platform: all articles are published open access; the publishing and peer-review processes are fully transparent; and authors are asked to include detailed descriptions of methods and to provide full and easy access to source data underlying the results to improve reproducibility.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
